tradingkey.logo

Telomir Pharmaceuticals Inc

TELO
View Detailed Chart
1.150USD
+0.030+2.68%
Close 02/06, 16:00ETQuotes delayed by 15 min
38.91MMarket Cap
LossP/E TTM

Telomir Pharmaceuticals Inc

1.150
+0.030+2.68%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.68%

5 Days

+0.88%

1 Month

-20.69%

6 Months

-37.50%

Year to Date

-13.53%

1 Year

-74.56%

View Detailed Chart

Key Insights

Telomir Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 128 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 15.50.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Telomir Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking
128 / 159
Overall Ranking
487 / 4521
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Telomir Pharmaceuticals Inc Highlights

StrengthsRisks
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -3.14, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.37M shares, decreasing 25.79% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.14M shares of this stock.

Analyst Rating

Based on 0 analysts
--
Current Rating
15.500
Target Price
+1283.93%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Telomir Pharmaceuticals Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Telomir Pharmaceuticals Inc Info

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
Ticker SymbolTELO
CompanyTelomir Pharmaceuticals Inc
CEOAminov (Erez)
Websitehttps://telomirpharma.com/
KeyAI